Selective, siRNA-Mediated Knockdown of CB1 Receptors in Macrophages for the Treatment of Diabetes
- Detailed Technology Description
- Novel compositions and methods for the treatment of type 2 diabetes mellitus using glucan-encapsulated siRNA directed against human cannabinoid receptor 1 (CB1). The glucan-encapsulated siRNA's spe
- Countries
- Not Available
- Application No.
- None
- *Abstract
-
Novel compositions and methods for the treatment of type 2 diabetes mellitus using glucan-encapsulated siRNA directed against human cannabinoid receptor 1 (CB1). The glucan-encapsulated siRNA's specifically target phagocytic macrophages upon administration.
- *IP Issue Date
- None
- *IP Type
- Other Patent
- Country/Region
- USA
For more information, please click Here